HGH Fragment 176-191: The Fat-Burning Tail of Growth Hormone

TL;DR: HGH Fragment 176-191 — the “HGH Frag” or “Frag 176-191” you keep seeing in fat-loss circles — is literally the last 16 amino acids of human growth hormone (residues 176 through 191). Researchers isolated this tail because it appears to carry the hormone’s lipolytic (fat-mobilizing) signal without the blood-sugar and IGF-1 baggage of the full molecule. It is the parent sequence that AOD-9604 was engineered from. The catch: almost all of the evidence is preclinical, and the “fat-burning fragment” reputation leans heavily on animal and cell data plus its more-studied cousin.

What HGH Fragment 176-191 actually is

Human growth hormone is a 191-amino-acid protein. Back in the late 1970s and 1980s, a Melbourne research group led by F.M. Ng and colleagues went looking for which part of that big molecule was responsible for its effect on fat. They chopped GH into pieces and tested them, and the C-terminal region — the stretch running from position 176 to 191 — kept showing up as the lipolytic hotspot.

So “Frag 176-191” is not a designed drug in the traditional sense. It is a synthetic copy of a naturally occurring segment of GH: no extra residues, no modifications, just those 16 amino acids reproduced in a lab. That is the whole pitch behind the nickname “the fat-burning fragment” — it is meant to be the part of growth hormone that touches fat, snipped away from the parts that do everything else.

The “lipolysis without the GH side effects” idea

Full-length growth hormone does a lot of things at once. It drives IGF-1 production (the anabolic, growth-promoting arm), it can raise blood glucose and blunt insulin sensitivity, and it stimulates tissue growth broadly. For a researcher interested purely in fat metabolism, that is a noisy signal.

The rationale for Frag 176-191 is selectivity. In preclinical models the fragment appears to stimulate lipolysis and fat oxidation while showing little to no measurable binding at the growth-hormone receptor in standard assays — meaning it does not seem to switch on the IGF-1 axis or the glucose effects the way intact GH does. Mechanistically the leading hypothesis points to beta-3 adrenergic receptor (β3-AR) signaling in adipose tissue: the fragment seems to nudge fat cells toward releasing and burning stored lipid, and to dampen lipogenesis (new fat storage).

HGH Frag vs. full growth hormone

The appeal is easiest to see side by side. Full GH is a broad metabolic hormone; the fragment is a narrow slice of it.

In other words: strip GH down to its C-terminus and, at least in the lab, you keep much of the fat-mobilizing behavior while largely losing the growth and glucose effects. That is the entire reason the fragment exists as a research tool.

HGH Frag 176-191 vs. AOD-9604

This is the comparison people search for most, and it is genuinely important. AOD-9604 (short for “Anti-Obesity Drug 9604”) is not a different mechanism — it is a modified analog of the very same fragment. Scientists at Metabolic Pharmaceuticals in Australia took residues 176-191 and added a tyrosine residue to the N-terminus (with a disulfide bridge in the sequence), a tweak intended to improve conformational stability and resistance to enzymatic breakdown.

The practical upshot: the two are close cousins working through a similar β3-AR–linked lipolytic pathway, but AOD-9604 was the one carried furthest through formal development, including human safety work. A lot of what gets attributed to plain HGH Frag in forums is actually extrapolated from AOD-9604 studies. If you want the deeper dive, see what AOD-9604 is and the AOD-9604 5mg reference page.

Research context and honest limits

Here is where the “fat-burning fragment” hype needs a reality check:

• The strongest data is preclinical. The foundational work — Ng and colleagues on lipolytic C-terminal fragments, and the Heffernan group on the modified fragment in obese mice and β3-AR knockout mice — is animal and cell research. It is real and it is interesting, but it is not the same as controlled human fat-loss outcomes.
• The unmodified fragment has little human trial data of its own. Most human-relevant evidence sits with AOD-9604, not Frag 176-191 specifically.
• Oral and clinical translation has been underwhelming. Even AOD-9604, the better-funded version, did not deliver knockout weight-loss results in later human obesity trials — a useful caution against assuming the raw fragment does more.

So the accurate framing is: a mechanistically elegant research peptide with a compelling selectivity story and a thin human evidence base. That is exactly why it stays in the research-use lane.

For anyone modeling reconstitution or working out concentration math for a study, the peptide calculator handles the mcg-per-unit arithmetic, and the HGH Frag 176-191 5mg page covers the specific vial format.

Frequently Asked Questions

What is HGH Fragment 176-191 in simple terms?

It is a synthetic copy of the last 16 amino acids (residues 176-191) of human growth hormone — the C-terminal “tail” that early research linked to the hormone’s fat-mobilizing activity. It is studied as a way to isolate that lipolytic signal from GH’s growth and blood-sugar effects.

How is HGH Frag different from AOD-9604?

AOD-9604 is a modified version of the same fragment, with an added tyrosine residue at the N-terminus for greater stability. HGH Frag 176-191 is the native, unmodified sequence. Both are thought to work through beta-3 adrenergic receptor signaling in fat tissue, but AOD-9604 has the more developed research record.

Why is it called “the fat-burning fragment”?

Because it corresponds to the segment of growth hormone that preclinical studies associated with lipolysis and fat oxidation, seemingly without the IGF-1 and glucose effects of the full hormone. The nickname captures the selectivity idea, not a proven clinical outcome.

Does HGH Fragment 176-191 have strong human evidence?

No. The bulk of the evidence is preclinical (rodent and adipocyte studies), and most human-relevant data comes from its analog AOD-9604 rather than the unmodified fragment itself.

Is Frag 176-191 the same as growth hormone?

No. It is only a small piece of the GH molecule. In research models it lacks meaningful growth-hormone-receptor activity, which is precisely the point — it is meant to carry the fat signal without the broader hormonal action of intact GH.

References

1. Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. American Journal of Physiology. 1978;234(5):E521-E526.
2. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278.
3. Heffernan MA, Thorburn AW, Fam B, Summers RJ, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442-1449.
4. Heffernan M, Summers RJ, Josephy A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-adrenergic receptor knock-out mice. Endocrinology. 2001;142(12):5182-5189.

This article is provided as a research and educational reference only; HGH Fragment 176-191 is not an approved medicine, nothing here is medical advice, and it is not for human consumption.